| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
P3 Health Partners Inc. Common Stock$11.99
+0.68 (+6.01%)
Market Cap
18.32 M
EPS
-45.20
P/E Ratio
-0.06 $
Value Trade
3.04 M
SEC Financials
Q1 2026Dilution Risk
Revenue
386.39 M
Operating CF
-27.47 M
Total Assets
674.16 M
Total Liabilities
807.32 M
Equity
-143.55 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
26.10 M
Monthly Burn
9.16 M
Runway
1.8 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
17.98 K
52 Week Range
1.52 - 11.30
% held by Insiders
56.91 %
% held by Institutions
7.32 %
Enterprise Value
294.80 M
Total Shares
3.32 M
Short %
11.6 %
Float Shares
1.19 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PIII
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
P3 Health Partners Inc. Common Stock (PIII) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
PIII
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PIII
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PIII
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PIII Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PIII Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-PIII
May 15, 2026Document EX 99.1 P3 HEALTH PARTNERS INC. and SUBSIDIARIES PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET (in thousands, except per share amounts) (unaudited)
P3 Health Partners Inc. released a pro forma condensed consolidated balance sheet reflecting significant changes. The total assets increased to $704,157, incorporating a $30,000 Series D preferred stock issuance. However, the total liabilities, despite a debt conversion, reflect a concerning level. The company's accumulated deficit remains notably high, raising questions about future financial stability.
Read more →-PIII
May 14, 2026P3 Health Partners Announces First Quarter 2026 Results
P3 Health Partners has announced its financial results for the first quarter of 2026. The article provides limited details, focusing primarily on the announcement itself without elaborating on specific financial metrics or performance indicators.
Read more →-PIII
Apr 16, 2026P3 Health Partners Schedules First Quarter 2026 Earnings Release and Conference Call
P3 Health Partners has announced the scheduling of its earnings release for the first quarter of 2026, along with a conference call. This event is expected to provide insights into the company's financial performance and strategic direction. Further details regarding the time and access to the call will be shared closer to the date.
Read more →-PIII
Mar 26, 2026P3 Health Partners Announces Fourth Quarter and Full Year 2025 Results Providing 2026 Guidance, Indicating a $10 Million Adjusted EBITDA Midpoint Management to Host Conference Call and Webcast
P3 Health Partners Inc. has announced its financial results for Q4 and the full year of 2025, highlighting a significant net loss and a decline in at-risk membership. The company reported total revenue growth but also faced increased Adjusted EBITDA losses. Looking forward, P3 provided guidance for 2026 that anticipates considerable year-over-year improvements in EBITDA, alongside a path to potential profitability. Despite these challenges, management remains optimistic about strategic positioning and future growth prospects.
Read more →-PIII
Nov 14, 2025P3 Health Partners Announces Third Quarter 2025 Results P3 Reports Continued Operational Progress and Expansion of Care Enablement Model in a Transitional Year $120 to $170 Million EBITDA Expansion Opportunity Strengthen
P3 Health Partners announced its third quarter 2025 results, showcasing operational progress amidst financial challenges. The company's Care Enablement Model is seen as a pivotal factor driving positive momentum, with significant EBITDA expansion opportunities projected. However, the report also highlighted a 10% decline in average at-risk membership and a total revenue decrease of 5%, raising concerns about the overall financial health moving forward. The management remains optimistic about executing their growth strategies aiming for profitability in 2026.
Read more →-PIII
Aug 14, 2025P3 Health Partners Announces Second Quarter 2025 Results Core Business Demonstrates Strength with Flat Medical Cost Trends Despite Industry Inflation $120-$170 Million in Additional EBITDA Opportunities Identified for 20
P3 Health Partners reported its second quarter 2025 financial results, showcasing a resilient core business with flat medical cost trends despite industry challenges. The company has identified significant EBITDA opportunities ranging from $120 to $170 million for 2026. However, it also faced a 6% decline in total revenue and a 9% decrease in average at-risk membership compared to the prior year, leading to an Adjusted EBITDA loss. The management remains optimistic about the company's financial trajectory, supported by improved funding on a per-member basis.
Read more →-PIII
May 15, 2025P3 Health Partners Announces First Quarter 2025 Results Affirming 2025 guidance Management to Host Conference Call and Webcast
P3 Health Partners has reported its financial results for the first quarter of 2025, affirming its 2025 guidance. The company saw a decrease in average at-risk membership by 8% compared to the previous year, and total revenue fell 4% year-over-year. Despite this, management highlights positive steps forward, including that three out of four markets reached breakeven or better during the quarter. However, Adjusted EBITDA losses expanded compared to the first quarter of the prior year. The management is committed to leveraging technology and enhancing care programs as part of their long-term strategic vision.
Read more →-PIII
Mar 27, 2025P3 Health Partners Announces Fourth Quarter and Full Year 2024 Results Revenue increased 18% year-over-year to $1.50 billion Affirming 2025 guidance Management to Host Conference Call and Webcast
P3 Health Partners reported its financial results for the fourth quarter and full year of 2024, highlighting an 18% increase in revenue to $1.50 billion. The company's at-risk membership also grew by approximately 14%, indicating positive market engagement. However, challenges persisted with a net loss that broadened significantly compared to the previous year. Despite these hurdles, management is optimistic, affirming guidance for 2025, suggesting plans for continued growth and financial sustainability.
Read more →-PIII
Feb 13, 2025P3 Health Partners Provides Preliminary 2025 Guidance and Announces Proposed Financing Transaction Company provides preliminary 2025 guidance and advance notification of a proposed financing transaction to provide a $30
P3 Health Partners has released preliminary guidance for 2025, predicting revenues between $1.35 billion and $1.5 billion and Adjusted EBITDA of negative $35 million to $5 million. The company is pursuing a financing transaction with its largest shareholder to secure $30 million, aiming to bolster liquidity. Despite anticipated progress towards profitability, the company acknowledges significant operational risks that could affect its financial results. A definitive 2025 guidance will follow the fourth quarter 2024 earnings report.
Read more →-PIII
Nov 12, 2024P3 Health Partners Announces Third Quarter 2024 Results Revenue increased 26% year-over-year to $362.1 million Third quarter results were affected by lower risk adjustments, higher medical expenses in the current year, a
P3 Health Partners announced a 26% increase in revenue for the third quarter of 2024, reaching $362.1 million. Despite this growth, the company faced significant challenges including higher medical expenses and a net loss of $102.9 million. Management is pursuing strategic initiatives to enhance profitability but has withdrawn its previous financial guidance due to adverse conditions. A conference call is scheduled for November 12, 2024, to discuss these results further.
Read more →-PIII
Aug 7, 2024P3 Health Partners Announces Second Quarter 2024 Results Management to Host Conference Call and Webcast
P3 Health Partners reported its financial results for the second quarter of 2024, noting a 15% increase in total revenue to $379.2 million. Despite the revenue growth, the company faced challenges such as a drop in gross profit and an increase in net loss compared to the previous year. CEO Aric Coffman highlighted ongoing initiatives aimed at enhancing capabilities for sustainable profitability. The company also issued guidance for the remainder of the fiscal year.
Read more →-PIII
May 8, 2024P3 Health Partners Announces First Quarter 2024 Results Dr. Aric Coffman joins P3 Health Partners as CEO Total revenue growth of 29% year-over-year Reaffirming 2024 guidance Anticipates reaching Adjusted EBITDA positive
P3 Health Partners has reported a robust 29% increase in total revenue for Q1 2024 compared to the same period last year. The company's newly appointed CEO, Dr. Aric Coffman, emphasized the potential for sustainable value creation and profitability. Despite the strong revenue growth, P3 experienced a net loss of $49.6 million, although this was an improvement from the prior year's loss. The company reaffirmed its optimistic guidance for the remainder of 2024.
Read more →-PIII
Mar 28, 2024P3 Health Partners Announces Fourth Quarter and Full Year 2023 Results Total revenue growth of 21% year-over-year, beating our 2023 guidance Affirming 2024 guidance Anticipates reaching Adjusted EBITDA positive in 2024 M
P3 Health Partners reported a strong financial performance for the fourth quarter and full year 2023, achieving a total revenue of $1.27 billion, representing a 21% growth from the previous year. The company affirmed its 2024 guidance, projecting continued growth in revenue and membership. Despite posting a net loss of $69.1 million in Q4, improvements in gross profit and medical margins were noted. The firm anticipates becoming Adjusted EBITDA positive in 2024, suggesting a positive outlook for its operational growth.
Read more →-PIII
Jan 9, 2024Document P3 Health Partners Reaffirms Guidance for 2023 and Announces Guidance for 2024 Henderson, NV
P3 Health Partners Inc. has reaffirmed its guidance for 2023 and provided new guidance for 2024 during the J.P. Morgan Healthcare Conference. The company anticipates achieving meaningful profitability in 2024, with projected revenue growth from $1.45 billion to $1.55 billion. Additionally, they expect to increase their Medicare Advantage Members and improve their medical margins. The leadership emphasizes a robust pipeline of strategic partnerships as a driving force for growth.
Read more →-PIII
Nov 9, 2023REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and Board of Directors of P3 Health Partners Inc. (f/k/a Foresight Acquisition Corp.) Opinion on the Financial Statements We have audited the ac
P3 Health Partners Inc. has reported its financial statements audited for the periods ending December 2, 2021, and December 31, 2020. The reports highlight a significant net loss and raise concerns about the company's viability as a going concern, primarily due to insufficient cash and working capital. The financial condition is compounded by the need for a successful business combination for future operations. The auditors highlighted that the financial statements reflect these substantial uncertainties.
Read more →-PIII
Nov 8, 2023Document P3 Health Partners Announces Third-Quarter and Year-to-Date 2023 Results YTD total revenue growth of 16% Continued strong performance across markets, re-affirming 2023 guidance Provides preliminary 2024 Full-Yea
P3 Health Partners reported its financial results for the third quarter of 2023, demonstrating a year-to-date total revenue growth of 16% compared to the previous year. The company reaffirmed its guidance for 2023 and provided preliminary guidance for 2024, forecasting an Adjusted EBITDA of $20 million to $40 million. Despite the positive revenue growth, the company experienced an increase in net loss, which heightened by 43% year-over-year, while the gross profit improved significantly. The management will hold a conference call to discuss these results on November 8, 2023.
Read more →-PIII
Aug 7, 2023Document P3 Health Partners Announces Second-Quarter 2023 Results Management to Host Conference Call and Webcast
P3 Health Partners (NASDAQ: PIII) announced solid financial results for the second quarter of 2023, highlighting a notable 21.9% increase in capitated revenue year-over-year. The company reduced its net loss to $27.6 million from a staggering $903.1 million in the same quarter last year. Key metrics indicate a successful trajectory for P3's health management model, although the company still anticipates some financial losses going forward. A conference call to discuss these results is scheduled for August 7, 2023.
Read more →-PIII
May 10, 2023Document P3 Health Partners Announces First-Quarter 2023 Results - Capitated revenue increases 11% vs. the same period in the prior year - Q1 2023 operating loss improved 7% vs. the same period in the prior year - Q1 202
P3 Health Partners has reported its financial results for the first quarter of 2023, showing an 11% increase in capitated revenue year-over-year. The company has also noted a 7% improvement in operating loss and a substantial 58% rise in medical margin. Despite these positive trends, P3 Health Partners continues to face challenges with a net loss of $52.4 million. As a result of its strong quarter, the company has raised its Adjusted EBITDA guidance for the year.
Read more →-PIII
Mar 31, 2023P3 Health Partners Announces Fourth Quarter and Full-Year 2022 Results Affirming 2023 guidance - introducing year-end medical margin guidance Anticipates reaching Adjusted EBITDA positive in early 2024 Management to Host
P3 Health Partners Inc. reported its fourth quarter and full-year 2022 financial results, highlighting a 65% increase in network contributions compared to 2021. The company announced its guidance for 2023 along with the introduction of new non-GAAP financial metrics, including medical margin and network contribution. P3 expects to reach Adjusted EBITDA profitability in early 2024, supported by a solid financing deal and a strategic focus on persistent lives and reduced operating expenses. A conference call to discuss these results and future outlook will occur on March 31, 2023.
Read more →-PIII
Mar 14, 2023P3 Health Partners Affirms 2023 Outlook and Schedules Earnings Call for 2022 Results Henderson, Nev.
P3 Health Partners Inc. has announced its reaffirmation of the 2023 outlook and plans to file its Annual Report on Form 10-K by March 30, 2023. The delay in filing is administrative due to the late audit for 2021, affecting the schedule for the 2022 financial results. Company leadership remains optimistic about meeting previously disclosed financial goals despite these challenges.
Read more →-PIII
Jan 11, 2023P3 Health Partners Reaffirms Guidance For 2022 and Announces Guidance For 2023 Henderson, Nev.
P3 Health Partners Inc. has reaffirmed its full-year 2022 financial guidance and announced its guidance for 2023 during the J.P. Morgan Healthcare Conference. The company's CEO is scheduled to present information relevant to their financial outlook. P3 Health Partners emphasizes its commitment to improving healthcare outcomes through its expansive network of primary care providers. Their announcements reflect confidence in the sustainability of their operational growth and management strategies.
Read more →-PIII
Nov 14, 2022P3 Health Partners Provides Third-Quarter and Year-to-Date 2022 Financial Results Strong Third-Quarter YTD 2022 revenue growth of 59% compared to the Third-Quarter YTD 2021 At-risk Medicare Advantage members exceeded 101
Health Partners Provides Third-Quarter and Year-to-Date 2022 Financial Results 2022 4:15 PM Eastern Standard Time Nev.--(BUSINESS WIRE)--P3 Health Partners, Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company,
Read more →-PIII
Oct 20, 2022P3 Health Partners Provides Second-Quarter and Year-to-Date 2022 Financial Results Increases 2022 Revenue Outlook Strong First-Half 2022 revenue growth of 84% compared to the First-Half 2021 At-risk Medicare Advantage me
Provides Second-Quarter and Year-to-Date 2022 Increases 2022 Revenue Outlook NV, October 20, 2022 (BUSINESS WIRE) -- P3 Health Partners, Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its
Read more →-PIII
Oct 4, 2022P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company's Securities The Company Intends to
P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company's Securities The Company Intends to Submit All Periodic Reports and Hold an Earnings Call
Read more →-PIII
Aug 19, 2022P3 Health Partners Announces Receipt of Nasdaq Notice Regarding Late Filing of Periodic Report Henderson, NV
P3 Health Partners Announces Receipt of Nasdaq Notice Regarding Late Filing of Periodic Report NV, August 19, 2022 (GLOBE NEWSWIRE) -P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today
Read more →-PIII
May 24, 2022P3 Health Partners Announces Receipt of Nasdaq Notice Regarding Late Filing of Periodic Reports Henderson, NV
P3 Health Partners Announces Receipt of Nasdaq Notice Regarding Late Filing of Periodic Reports Henderson, NV, May 24, 2022 (GLOBE NEWSWIRE) -- P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management co
Read more →-PIII
Apr 14, 2022P3 Health Partners to Present Fourth Quarter and Full Year 2021 Financial Results Management to Host Conference Call and Webcast
P3 Health Partners to Present Fourth Quarter and Full Year 2021 Financial Results Management to Host Conference Call and Webcast April 25, 2022 at 4:30 PM ET NV, April 14, 2022 - P3 Health Partners, Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physicia
Read more →-PIII
Mar 9, 2022P3 Health Partners Announces Select Preliminary Fourth Quarter and Full Year 2021 Results, and Introduces 2022 Outlook Strong revenue growth of 46% for the fourth quarter and 32% for full year 2021 Full year 2022 revenue
P3 Health Partners Announces Select Preliminary Full Year 2021 Results, and Introduces 2022 Outlook Strong revenue growth of 46% for the fourth quarter and 32% for full year 2021 Full year 2022 revenue expected to be up to $1 billion, a 56% increase vs. prior year At-risk M
Read more →-PIII
Dec 28, 2021Who: People with Passion and Purpose What: Dedicated to Transforming Healthcare for Patients, Providers, and Payors How: Patient-Centric, Physician-Led, and Population Health Management Focused J.P. Morgan Healthcare Con
Value-Based Care Physician Enablers1 ~68k ~210k ~109k ~85k ~31k ~26k % of Total Medicare Advantage Enrollment2 ~2% of ~24mm MA enrollees 9 Proven Outcomes And Physician-Led We are able to drive enhanced outcomes via our patient- centric, physician-led care model: 35% / 36% Reduct
Read more →-PIII
Dec 9, 2021P3 HEALTH GROUP HOLDINGS, LLC and SUBSIDIARIES CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021 and 2020 1 P3 HEALTH GROUP HOLDINGS, LLC and SUBSIDIARIES COND
HOLDINGS, LLC and SUBSIDIARIES CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AND NINE MONTHS ENDED SEPTEMBER 30, 2021 and 2020 HOLDINGS, LLC and SUBSIDIARIES CONDENSED CONSOLIDATED ASSETS Unaudited September 30, 2021 December 31, 2020 CURRENT ASSETS:
Read more →-PIII
Sep 22, 2021P3 Analyst Day Presentation September 2021 Who: People with Passion and Purpose What: Dedicated to Transforming Healthcare for Patients, Providers, and Payors How: Patient-Centric, Physician-Led, and Population Health Ma
Passion and Purpose What: Dedicated to Transforming Healthcare for Patients, Providers, and Payors How: Patient-Centric, Physician-Led, and Population Health Management FocusedExhibit 99.1 P3 Analyst Day Presentation September 2021 Who: People with Passion and Purpose What: Dedi
Read more →-PIII
May 25, 2021P3 Health Partners to Become Publicly Traded via Merger with Foresight Acquisition Corp. - Transaction to Publicly List P3 Health Partners, a Patient-Centered and Physician-Led Population Health Management Company Delive
P3 Health Partners to Become Publicly Traded via Merger with Foresight Acquisition Corp. - Transaction to Publicly List P3 Health Partners, a Patient-Centered and Physician-Led Population Health Management Company Delivering Value-Based Care - Estimated Post-Transaction Enterp
Read more →-PIII
Feb 12, 2021INDEX TO FINANCIAL STATEMENT Page Audited Financial Statement of Foresight Acquisition Corp.: Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
INDEX TO FINANCIAL STATEMENT Page Audited Financial Statement of Foresight Acquisition Corp.: Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of February 12, 2021 F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED
Read more →-PIII
Feb 10, 2021Foresight Acquisition Corp. Announces Pricing of $275,000,000 Initial Public Offering Foresight Acquisition Corp. (the Company ), a blank check company targeting a technology-enabled consumer or consumer healthcare busin
Foresight Acquisition Corp. Announces Pricing of $275,000,000 Initial Public Offering Foresight Acquisition Corp. (the Company ), a blank check company targeting a technology-enabled consumer or consumer healthcare business, announced today the pricing of its initial public off
Read more →Competitive Position
How PIII ranks across every disease it competes inCompetitive Position is a premium feature
See how PIII ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial